Results 121 to 130 of about 48,475 (244)

Peer Review #2 of "Extensive protein expression changes induced by pamidronate in RAW 264.7 cells as determined by IP-HPLC (v0.1)"

, 2020
Sang Yup Lee, Soung Kim, Yeon Kim, Suk Keun, Lee Corresp, Suk Lee, Sang‐Uk Lee, Suk Lee, Suk Lee, A Abelson, C Acevedo, H Bale, B Gludovatz, A Wat, S Tang, M Wang, B Busse, E Zimmermann, E Schaible, M Allen, D Burr, R Ritchie, Z Akram, T Abduljabbar, S Kellesarian, M Abu Hassan, F Javed, F Vohra, N Alqhtani, N Logan, S Meghji, R Leeson, P Brett, Ariza Jimenez, A Nunez Cuadros, E Galindo Zavala, R Nunez Caro, L Diaz-Cordobes, G Rego, Urda Cardona, A, J Ata-Ali, F Ata-Ali, D Penarrocha-Oltra, P Galindo-Moreno, N Bhavsar, S Trivedi, K Dulani, N Brahmbhatt, S Shah, D Chaudhri, D Burr, M Allen, D Carmagnola, E Canciani, D Sozzi, F Biglioli, L Moneghini, C Dellavia, M Cecchini, R Felix, H Fleisch, P Cooper, C Chen, M Xia, L Wu, C Zhou, F Wang, Z Chen, L Cheng, G Feng, M Chevreau, X Romand, P Gaudin, R Juvin, A Baillet, P Chirappapha, S Kitudomrat, T Thongjood, R Aroonroch, W Choi, J Lee, H Yoon, C Min, S Lee, N Clarke, A Tomlinson, Y Ohyagi, S Younkin, S Naylor, F Ebetino, A Hogan, S Sun, M Tsoumpra, X Duan, J Triffitt, A Kwaasi, J Dunford, B Barnett, U Oppermann   +99 more
openalex   +2 more sources

Evaluation of Two Different Pamidronate Treatment Protocols in Children with Osteogenesis Imperfecta

Çukurova Üniversitesi Tıp Fakültesi Dergisi, 2014
Purpose: Osteogenesis imperfecta is an inherited disorder of connective tissue. Children with this condition suffer from recurrent fractures, deformities, osteoporosis and pain.
Neslihan Onenli Mungan, Fatih Gurbuz, Eda Mengen, Ozden Ozgur, Ali Kemal Topaloglu, Bilgin Yuksel   +5 more
doaj  

Pamidronate Does not Affect Cortical Porosity in Transgenic Mice Overexpressing Osteoblastic Gαs

, 2019
G-protein coupled receptors are involved in many signal transduction pathways. The Gαs protein becomes activated following ligand binding, to stimulate downstream adenylyl cyclase. Previously, Zhang et al.
Poon, Antonella
core   +1 more source

Pamidronate for SAPHO syndrome [PDF]

Rheumatology, 2003
openaire   +2 more sources

Evaluation of adverse experiences related to pamidronate infusion in Paget’s disease of bone.

, 1998
Pamidronate disodium, a second generation bisphosphonate, has been found to be safe as well as effective in the treatment of Paget's disease of bone.1 It is licensed in the UK and many other countries for the intravenous treatment of Paget's disease ...
DAVISON, C, Richardson, P. C., Davison, C. E., MERCER, S, Mercer, S. J., Hollis, Sally, BUCKLER, H, RICHARDSON, P, Buckler, H. M., ANDERSON, D   +9 more
core  

Management of bone metastases in patients with breast cancer: review of bone-modifying therapy, emerging new agents, and future directions. [PDF]

Front Oncol
Bader G, Brown B, Davenport AP, Gatti-Mays M, Johnson KC, Lopetegui-Lia N, Quiroga D, Roy AM, Sardesai S, Stover D, Wesolowski R.   +10 more
europepmc   +1 more source

Pamidronate may prevent muscle protein breakdown in burns by indirectly affecting cytokines [PDF]

, 2016
Jason W. Jay, David N. Herndon, Celeste C. Finnerty, Clark R. Andersen, Gordon L. Klein   +4 more
openalex   +1 more source

Effectiveness and safety of neridronate in chronic nonbacterial osteomyelitis: insight from the CAMELOT registry. [PDF]

Ther Adv Musculoskelet Dis
Marino A, Amati A, Di Taranto R, Pireddu D, Grillo G, Baldo F, Costi S, Crotti C, Curti A, Vincenzo Z, Gallazzi MB, Varenna M, Caporali R, Chighizola CB.   +13 more
europepmc   +1 more source

Dyselectrolytemias after single dose of pamidronate administration.

, 2012
Keshav Panday, Rajan Kanth
openalex   +2 more sources

Bone-modifying therapy in multiple myeloma: a comprehensive review. [PDF]

Front Oncol
Bogeljić Patekar M, Milunović V, Mandac Smoljanović I, Bašić Kinda S, Ostojić Kolonić S, Radić-Krišto D, Gašparov S, Baljevic M.   +7 more
europepmc   +1 more source